培美曲塞在复发性上皮性卵巢癌中的作用：一项范围综述。
The role of pemetrexed in recurrent epithelial ovarian cancer: A scoping review.
作者信息
Roche Michael, Parisi Laura, Li Linda, Knehans Amy, Phaeton Rebecca, Kesterson Joshua P
机构信息
Department of Obstetrics and Gynecology, Penn State Hershey Medical Center, Hershey, Pennsylvania.
Department of Obstetrics and Gynecology, The University of Kansas Medical Center, Kansas City, Kansas.
出版信息
Oncol Rev. 2018 Mar 21;12(1):346. doi: 10.4081/oncol.2018.346. eCollection 2018 Jan 30.
Abstract
Ovarian cancer is the leading cause of mortality among gynecologic malignancies, with most cases diagnosed at an advanced stage. Despite an initial response, most develop a recurrence and subsequent resistance to standard therapies. Pemetrexed (Alimta) is a new generation multi-targeted antifolate initially approved for the treatment of malignant pleural mesothelioma. In recent years, it has shown promise in the treatment of recurrent epithelial ovarian cancer. In this review, we outline the current literature and discuss the future of pemetrexed in the setting of recurrent epithelial ovarian cancer.
摘要
卵巢癌是妇科恶性肿瘤中导致死亡的主要原因，大多数病例在晚期被诊断出来。尽管最初有反应，但大多数患者会复发并随后对标准疗法产生耐药性。培美曲塞（力比泰）是新一代多靶点抗叶酸药物，最初被批准用于治疗恶性胸膜间皮瘤。近年来，它在复发性上皮性卵巢癌的治疗中显示出前景。在本综述中，我们概述了当前的文献，并讨论了培美曲塞在复发性上皮性卵巢癌治疗中的未来。
相似文献
1
The role of pemetrexed in recurrent epithelial ovarian cancer: A scoping review.培美曲塞在复发性上皮性卵巢癌中的作用：一项范围综述。
Oncol Rev. 2018 Mar 21;12(1):346. doi: 10.4081/oncol.2018.346. eCollection 2018 Jan 30.
2
Pemetrexed therapy for malignant pleural mesothelioma.培美曲塞治疗恶性胸膜间皮瘤。
Ann Pharmacother. 2005 Apr;39(4):678-83. doi: 10.1345/aph.1E329. Epub 2005 Mar 8.
3
Pemetrexed (Alimta): improving outcomes in malignant pleural mesothelioma.培美曲塞（力比泰）：改善恶性胸膜间皮瘤的治疗效果。
Expert Rev Anticancer Ther. 2004 Jun;4(3):361-8. doi: 10.1586/14737140.4.3.361.
4
Phase II study of bevacizumab and pemetrexed for recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer.贝伐珠单抗联合培美曲塞治疗复发性或持续性上皮性卵巢癌、输卵管癌或原发性腹膜癌的 II 期研究。
Gynecol Oncol. 2013 Dec;131(3):535-40. doi: 10.1016/j.ygyno.2013.09.032. Epub 2013 Oct 4.
5
The 2020 Japan Society of Gynecologic Oncology guidelines for the treatment of ovarian cancer, fallopian tube cancer, and primary peritoneal cancer.《2020 年日本妇科肿瘤学会卵巢癌、输卵管癌和原发性腹膜癌治疗指南》
J Gynecol Oncol. 2021 Mar;32(2):e49. doi: 10.3802/jgo.2021.32.e49.
6
Pemetrexed (Alimta, MTA, multitargeted antifolate, LY231514) for malignant pleural mesothelioma.培美曲塞（力比泰、MTA、多靶点抗叶酸制剂、LY231514）用于治疗恶性胸膜间皮瘤。
Semin Oncol. 2003 Aug;30(4 Suppl 10):32-6. doi: 10.1016/s0093-7754(03)00283-5.
7
Pemetrexed: a multitargeted antifolate.培美曲塞：一种多靶点抗叶酸药物。
Clin Ther. 2005 Sep;27(9):1343-82. doi: 10.1016/j.clinthera.2005.09.010.
8
Evaluation of pemetrexed (Alimta, LY231514) as second-line chemotherapy in persistent or recurrent carcinoma of the cervix: the CERVIX 1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) Group.培美曲塞（力比泰，LY231514）作为持续性或复发性宫颈癌二线化疗的评价：MITO（多中心意大利卵巢癌和妇科恶性肿瘤研究）组的 CERVIX 1 研究。
Ann Oncol. 2010 Jan;21(1):61-6. doi: 10.1093/annonc/mdp266. Epub 2009 Jul 15.
9
Incorporation of pemetrexed (Alimta) into the treatment of non-small cell lung cancer (thoracic tumors).培美曲塞（力比泰）纳入非小细胞肺癌（胸部肿瘤）的治疗。
Semin Oncol. 2002 Jun;29(3 Suppl 9):17-22. doi: 10.1053/sonc.2002.34268.
10
Revisiting cutaneous adverse reactions to pemetrexed.重新审视培美曲塞的皮肤不良反应。
Oncol Lett. 2011 Sep 1;2(5):769-772. doi: 10.3892/ol.2011.352. Epub 2011 Jul 5.
引用本文的文献
1
Targeting Oncometabolites in Peritoneal Cancers: Preclinical Insights and Therapeutic Strategies.靶向腹膜癌中的肿瘤代谢物：临床前见解与治疗策略
Metabolites. 2023 Apr 30;13(5):618. doi: 10.3390/metabo13050618.
2
Folate Transport and One-Carbon Metabolism in Targeted Therapies of Epithelial Ovarian Cancer.上皮性卵巢癌靶向治疗中的叶酸转运与一碳代谢
Cancers (Basel). 2021 Dec 31;14(1):191. doi: 10.3390/cancers14010191.
3
Cellular Fitness Phenotypes of Cancer Target Genes from Oncobiology to Cancer Therapeutics.从肿瘤生物学到癌症治疗的癌症靶基因的细胞健康表型。
Cells. 2021 Feb 18;10(2):433. doi: 10.3390/cells10020433.
4
Establishment and characterization of a new malignant peritoneal mesothelioma cell line, KOG-1, from the ascitic fluid of a patient with pemetrexed chemotherapy resistance.建立并鉴定一株来源于培美曲塞化疗耐药患者腹腔积液的恶性腹膜间皮瘤细胞系 KOG-1。
Hum Cell. 2020 Jan;33(1):272-282. doi: 10.1007/s13577-019-00286-w. Epub 2019 Oct 3.
本文引用的文献
1
A Phase I Study of the Non-Receptor Kinase Inhibitor Bosutinib in Combination with Pemetrexed in Patients with Selected Metastatic Solid Tumors.一项评估非受体酪氨酸激酶抑制剂波舒替尼联合培美曲塞治疗特定转移性实体瘤患者的 I 期临床研究。
Curr Oncol. 2022 Dec 3;29(12):9461-9473. doi: 10.3390/curroncol29120744.
2
Cancer Statistics, 2017.《2017 年癌症统计》
CA Cancer J Clin. 2017 Jan;67(1):7-30. doi: 10.3322/caac.21387. Epub 2017 Jan 5.
3
MicroRNA 25, microRNA 145, and microRNA 210 as biomarkers for predicting the efficacy of maintenance treatment with pemetrexed in lung adenocarcinoma patients who are negative for epidermal growth factor receptor mutations or anaplastic lymphoma kinase translocations.微小RNA 25、微小RNA 145和微小RNA 210作为预测培美曲塞维持治疗对表皮生长因子受体突变阴性或间变性淋巴瘤激酶易位阴性的肺腺癌患者疗效的生物标志物。
Transl Res. 2016 Apr;170:1-7. doi: 10.1016/j.trsl.2015.11.006. Epub 2015 Nov 24.
4
Thymidylate synthase expression as a predictive biomarker of pemetrexed sensitivity in advanced non-small cell lung cancer.胸苷酸合成酶表达作为晚期非小细胞肺癌培美曲塞敏感性的预测生物标志物。
BMC Pulm Med. 2015 Oct 26;15:132. doi: 10.1186/s12890-015-0132-x.
5
Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin According to Thymidylate Synthase Expression in Nonsquamous Non-Small-Cell Lung Cancer: A Biomarker-Stratified Randomized Phase II Trial.培美曲塞联合顺铂与吉西他滨联合顺铂治疗非鳞状非小细胞肺癌：根据胸苷酸合成酶表达的生物标志物分层随机 II 期试验。
J Clin Oncol. 2015 Aug 1;33(22):2450-6. doi: 10.1200/JCO.2014.59.9324. Epub 2015 Jun 29.
6
Pemetrexed for ovarian cancer: a systematic review of the published literature and a consecutive series of patients treated in a nonclinical trial setting.培美曲塞用于治疗卵巢癌：已发表文献的系统评价及在非临床试验环境中治疗的连续系列患者
Case Rep Oncol. 2014 Jul 30;7(2):541-9. doi: 10.1159/000365885. eCollection 2014 May.
7
Prognostic value of serum leptin in advanced lung adenocarcinoma patients with cisplatin/pemetrexed chemotherapy.血清瘦素在晚期肺腺癌患者顺铂/培美曲塞化疗中的预后价值
Oncol Lett. 2014 Jun;7(6):2073-2078. doi: 10.3892/ol.2014.1988. Epub 2014 Mar 21.
8
Phase II study of bevacizumab and pemetrexed for recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer.贝伐珠单抗联合培美曲塞治疗复发性或持续性上皮性卵巢癌、输卵管癌或原发性腹膜癌的 II 期研究。
Gynecol Oncol. 2013 Dec;131(3):535-40. doi: 10.1016/j.ygyno.2013.09.032. Epub 2013 Oct 4.
9
Thymidylate synthase expression and outcome of patients receiving pemetrexed for advanced nonsquamous non-small-cell lung cancer in a prospective blinded assessment phase II clinical trial.在一项前瞻性盲法评估的 II 期临床试验中，接受培美曲塞治疗的晚期非鳞状非小细胞肺癌患者的胸苷酸合成酶表达与结局。
J Thorac Oncol. 2013 Jul;8(7):930-9. doi: 10.1097/JTO.0b013e318292c500.
10
Phase I trial of intraperitoneal pemetrexed, cisplatin, and paclitaxel in optimally debulked ovarian cancer.腹腔内注射培美曲塞、顺铂和紫杉醇治疗最大程度减瘤的卵巢癌的 I 期临床试验。
Clin Cancer Res. 2012 May 1;18(9):2668-78. doi: 10.1158/1078-0432.CCR-12-0261. Epub 2012 Mar 15.
Zotero 插件